Resistance training cuts muscle loss by 1.1 kg during tirzepatide therapy
A 40-week trial of 120 adults shows that pairing the drug with three weekly workout sessions preserves lean tissue and builds strength.
By Ama Ndlovu ·

Adults taking tirzepatide lost an average of 1.1 kilograms more lean soft tissue than those who combined the medication with resistance training, according to a randomized trial published in Nature Medicine on November 9. The study, led by researchers at the University of Western Australia, tracked 120 participants over 40 weeks.
All participants received the drug, which is the active ingredient in Mounjaro and Zepbound. Half were assigned to three resistance training sessions per week, while the other half continued their usual activities. The cohort consisted of men and postmenopausal women aged 50 to 70 who had obesity or overweight with a related health condition. None of the participants had type 2 diabetes.
Both groups lost approximately 22 kilograms, or 49 pounds. The exercise group lost an average of 3.57 kilograms of lean tissue, whereas the medication-only group lost 4.67 kilograms. Strength outcomes also diverged between the two groups. Participants who trained showed improved upper and lower body strength, while those who took the medication alone experienced a decline in strength based on bench press and knee extension tests.
Tirzepatide acts on two hormone receptors involved in appetite and food intake. In the United States, Mounjaro is approved for type 2 diabetes, and Zepbound is approved for weight management. The trial participants in both groups received general guidance on protein, fiber, and hydration. The new data provides specific evidence regarding the type of physical activity recommended in Zepbound's US prescribing information.
Prof. Danny Green, the lead investigator, stated that treatment should aim to maintain physical function as weight comes off. He urged doctors to include resistance exercise in treatment plans. "We now know that muscle loss can be reduced and strength increased when regular resistance training is used alongside tirzepatide treatment," Green said in a university statement.
Eli Lilly supplied the medication for the study but had no role in designing, running, or evaluating the trial. Several authors disclosed payments or advisory relationships with pharmaceutical or nutrition companies. The researchers noted that the results apply to a structured exercise program in a specific patient group and cannot be automatically extended to other weight-loss drugs or exercise routines.
More Business · World news · Business Watchdog · Report a business · Got a Story?






